Clinical trials: Cerebral Disorder
Sub Arachnoid Hemorrhage, Vasospasm
An Innovative Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm
The lack of a precise diagnostic technique for cerebral vasospasm associated with traumatic brain injury (TBI) limits the ability to detect and treat this phenomenon.
- Trial name
- NCT02093182
- Where
- Israel
- Sponsor
- HeadSense Medical
Friedreich's Ataxia
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
The purpose of this long term extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia (FA).
- Trial name
- STEADFAST (NCT02797080)
- Testing
- interferon γ-1b
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Amgen
Stroke, Occupational Therapy
Virtual Activities of Living for Occupational Rehabilitation
Duke University will serve as the clinical research site for the Phase II RCT of the VALOR system, which enables telehealth delivery of evidence-based upper extremity (UE) stroke therapy in a patient's home using immersive VR…
- Conditions
- Stroke, Occupational Therapy, Activities of Daily Living, Rehabilitation
- Trial name
- VALOR (NCT07450586)
- Testing
- VALOR Home Exercise Program (HEP), Usual Care Treatment (UCT) Control
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barron Associates, Inc.
Alzheimer Disease or Associated Disorder, Dementia
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD.
- Conditions
- Alzheimer Disease or Associated Disorder, Dementia, Cognitive Decline
- Trial name
- NCT06850870
- Testing
- Door-through-door companion rideshare, Curb-to-curb rideshare services
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Onward Health, Inc
Intracranial Aneurysm
Coil Assisted Flow Diversion Safety and Performance Study
Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document the safety and performance of Neqstent in adjunctive therapy.
- Trial name
- CAFI (NCT04187573)
- Testing
- Neqstent
- Where
- 7 sites in Austria, Canada and 3 more
- Volunteers
- 38 people
- Sponsor
- Cerus Endovascular, Inc.
Low Back Pain, Migraine
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
- Conditions
- Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
- Trial name
- NCT00228605
- Testing
- OraVescent Fentanyl
- Where
- 38 sites in United States
- Volunteers
- 500 people
- Sponsor
- Cephalon
Fabry Disease
Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients
The objective of this study is to increase the understanding surrounding the choices presented to patients and families impacted by Fabry disease.
- Trial name
- NCT04804566
- Testing
- This is a non-interventional study
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Amicus Therapeutics
Parkinson Disease
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
This is a randomized, open-label, 2-sequence, 2-treatment cross-over study in healthy adult subjects. Rotigotine PK profiles will be obtained from all subjects after both a single dose of 28 mg LY03003 and 1 week of 4 mg q24h…
- Trial name
- NCT04384666
- Testing
- LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Multiple System Atrophy
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
- Trial name
- NCT07197866
- Testing
- TEV-56286
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 200 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Idiopathic Parkinson's Disease
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.
- Trial name
- BRIGHT (NCT01782222)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 122 people
- Sponsor
- UCB BIOSCIENCES GmbH
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients.
- Trial name
- NCT02129413
- Testing
- Delta system
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- Samson NeuroSciences
Stroke, Acute, Venous Thromboembolism
GEKO Venous Thromboembolism Prevention Study
This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to…
- Conditions
- Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT05476913
- Testing
- geko™ device
- Where
- 18 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- Firstkind Ltd
Partial Epilepsy
Cenobamate Expanded Access Program (EAP)
This Cenobamate Expanded Access Program (EAP) is designed to continue providing treatment with Cenobamate (YKP3089) to patients with partial-onset epilepsy that were enrolled in the SK Life Science clinical trial YKP3089C013…
- Trial name
- NCT04513860
- Testing
- YKP3089
- Sponsor
- SK Life Science, Inc.
Parkinson Disease
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
- Trial name
- NCT05581823
- Testing
- Tavapadon, Carbamazepine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Fabry Disease
Sophisticated Assessment of Disease Burden in Patients With Fabry Disease
To detect early signs of cardiac and metabolic alterations as well as to evaluate the progression of cardiac and metabolic impairments in mildly affected patients with Fabry Disease using high sensitive diagnostic methods.
- Trial name
- SOPHIA (NCT01210196)
- Testing
- MRI
- Where
- 11 sites in Belgium, Czechia and 4 more
- Volunteers
- 36 people
- Sponsor
- Shire
Parkinson Disease, Genetic Predisposition
Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.
- Trial name
- NCT04119596
- Testing
- 16S rRNA gene sequencing, DNA-microarray genotyping
- Where
- Russia
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Atlas Biomed
Drug Resistant Epilepsy, Seizure
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
To evaluate the safety and efficacy of using NaviFUS™ system in patients with drug resistant epilepsy
- Conditions
- Drug Resistant Epilepsy, Seizure, Seizure Disorder, Epilepsy
- Trial name
- NCT04999046
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- NaviFUS Corporation
Migraine
Efficacy and Safety of BGG492 in the Treatment of Migraine
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
- Trial name
- NCT00892203
- Testing
- BGG492, Sumatriptan
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Novartis
Hydrocephalus
Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device
This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow. Patients with an existing implanted shunt will wear the device to acquire longitudinal data.
- Trial name
- NCT06086561
- Testing
- Thermal Anisotropy Measurement Device
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- Rhaeos, Inc.
Acromegaly
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.
- Trial name
- NCT00372697
- Testing
- Octreotide acetate 30 mg suspension
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.